Ishita Drugs & Industries Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.10",
    "chg": -0.01,
    "chgp": "-0.01%",
    "dir": -1,
    "prev_price": "70.11",
    "mcapval": "20.96 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE806D01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "27 ",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Ishita Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ishita-drugs-3694511",
        "imagepath": "",
        "date": "2025-11-12 23:42:54",
        "description": "Answer:\nThe historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.\n\nBreakdown:\nIshita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20..."
      },
      {
        "title": "Are Ishita Drugs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-latest-results-good-or-bad-3693150",
        "imagepath": "",
        "date": "2025-11-12 19:26:54",
        "description": "Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter.\n\nThe operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector.\n\nDespite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo..."
      },
      {
        "title": "Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-financial-trend-declines-from-flat-to-negative-amid-weak-performance-indicators-3692418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_fintrenddot_3692418.png",
        "date": "2025-11-12 11:00:51",
        "description": "Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-sharp-sequential-decline-raises-concerns-despite-yoy-growth-3692504",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_quaterlyResult_3692504.png",
        "date": "2025-11-12 09:38:13",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space."
      }
    ],
    "total": 101,
    "sid": "444125",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter Ended 31St December 2025",
      "datetime": "30-Jan-2026",
      "details": "Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2025. 2. Any other matter with permission of the Chair.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31st December 2025 as attached.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Change In Address Of Registrar And Share Transfer Agent (RTA) (Ahmedabad Branch)",
      "datetime": "02-Jan-2026",
      "details": "Change in Address of our RTA i.e. Bigshare Services Private Limited (Ahmedabad Branch)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Ishita Drugs?

2025-11-12 23:42:54

Answer: The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years. Breakdown: Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20...

Are Ishita Drugs latest results good or bad?

2025-11-12 19:26:54

Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter. The operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector. Despite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo...

Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges

2025-11-12 11:00:51

Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market.

Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth

2025-11-12 09:38:13

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space.

View All News